GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Current Ratio
中文

Algernon Pharmaceuticals (XCNQ:AGN) Current Ratio : 0.04 (As of Nov. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Algernon Pharmaceuticals's current ratio for the quarter that ended in Nov. 2023 was 0.04.

Algernon Pharmaceuticals has a current ratio of 0.04. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Algernon Pharmaceuticals has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for Algernon Pharmaceuticals's Current Ratio or its related term are showing as below:

XCNQ:AGN' s Current Ratio Range Over the Past 10 Years
Min: 0.04   Med: 7.18   Max: 133
Current: 0.04

During the past 9 years, Algernon Pharmaceuticals's highest Current Ratio was 133.00. The lowest was 0.04. And the median was 7.18.

XCNQ:AGN's Current Ratio is ranked worse than
98.46% of 1555 companies
in the Biotechnology industry
Industry Median: 3.8 vs XCNQ:AGN: 0.04

Algernon Pharmaceuticals Current Ratio Historical Data

The historical data trend for Algernon Pharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Current Ratio Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Current Ratio
Get a 7-Day Free Trial Premium Member Only 0.76 12.75 4.80 1.12 0.13

Algernon Pharmaceuticals Quarterly Data
Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.19 0.24 0.13 0.04

Competitive Comparison of Algernon Pharmaceuticals's Current Ratio

For the Biotechnology subindustry, Algernon Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Current Ratio falls into.



Algernon Pharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Algernon Pharmaceuticals's Current Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Current Ratio (A: Aug. 2023 )=Total Current Assets (A: Aug. 2023 )/Total Current Liabilities (A: Aug. 2023 )
=0.34/2.72
=0.13

Algernon Pharmaceuticals's Current Ratio for the quarter that ended in Nov. 2023 is calculated as

Current Ratio (Q: Nov. 2023 )=Total Current Assets (Q: Nov. 2023 )/Total Current Liabilities (Q: Nov. 2023 )
=0.122/2.939
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (XCNQ:AGN) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Algernon Pharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals (XCNQ:AGN) Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (XCNQ:AGN) Headlines

No Headlines